Bausch Health Companies Inc (BHC : TSX)
Common Stock
$6.62
CAD
+0.05 (0.76%)
Last updated: 2026-06-22
BHC
Bausch Health Companies Inc
WealthAwesomePerformance
1 Day
+0.76%
1 Week
-5.16%
1 Month
-12.32%
YTD
-33.27%
Key Statistics
Market Cap
$2.45B
52W High
$11.97
52W Low
$6.45
P/E Ratio
-
50 Day MA
$7.48
200 Day MA
$8.45
Beta
0.41
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/22/2026 | $6.68 | $6.71 | $6.53 | $6.62 | $6.62 | 303,993 |
| 6/19/2026 | $6.73 | $6.74 | $6.57 | $6.57 | $6.57 | 317,708 |
| 6/18/2026 | $6.76 | $6.77 | $6.45 | $6.74 | $6.74 | 895,882 |
| 6/17/2026 | $6.93 | $7.00 | $6.71 | $6.72 | $6.72 | 495,722 |
| 6/16/2026 | $7.01 | $7.05 | $6.84 | $6.93 | $6.93 | 701,728 |
| 6/15/2026 | $7.11 | $7.23 | $6.95 | $6.98 | $6.98 | 522,668 |
| 6/12/2026 | $7.21 | $7.28 | $7.05 | $7.09 | $7.09 | 745,761 |
| 6/11/2026 | $7.18 | $7.34 | $7.18 | $7.20 | $7.20 | 246,769 |
| 6/10/2026 | $7.20 | $7.42 | $7.13 | $7.18 | $7.18 | 298,472 |
| 6/9/2026 | $7.16 | $7.32 | $7.09 | $7.22 | $7.22 | 373,208 |
Analyst Price Targets
Based on analyst covering BHC
Wall Street analysts forecast BHC stock price to rise 5.9% over the next 12 months.
Consensus
No RatingAvg. Target
C$7.01
+5.9% Upside
Current Price
C$6.62
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BHC's historical volatility
30-Day Vol
42.4%
Annualized
90-Day Vol
39.4%
Annualized
Trend (90d)
-28.2%
Annualized drift
90d Mean
C$5.99
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$6.40 | C$5.53 – C$7.41 |
| 60 trading days | C$6.19 | C$5.03 – C$7.61 |
| 90 trading days | C$5.99 | C$4.65 – C$7.71 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Bausch Health Companies Inc
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Financials
- Revenue (TTM)
- $10.53B
- EBITDA
- $3.61B
- Profit Margin
- -11.47%
- ROE (TTM)
- 43.64%
- EPS (Diluted)
- -4.57
- Book Value
- -7.70
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About BHC
Articles Featuring BHC.TO
Latest articles and analysis covering BHC.TO
Why Bausch Health Companies Inc stock is rising today
Bausch Health Companies Inc's stock rose by 2.04% today, closing at CA$6.75, signaling potential investor confidence ahead of upcoming financial results.
Why Bausch Health Companies Inc stock is sliding today
Bausch Health Companies Inc is experiencing a notable decline in its stock price today, raising concerns among investors about its future performance and stability.
Why Bausch Health Companies Inc stock is sliding today
Bausch Health Companies Inc experienced a notable decline in its stock price, dropping 3.03% in the last trading session. This decline comes amidst a backdrop of ongoing challenges for the company, which has yet to release recent financial results that could clarify its performance outlook.
Bausch Health Secures Key Agreement for Schizophrenia Treatment Coverage Across Canada
Bausch Health's agreement with the pan-Canadian Pharmaceutical Alliance could enhance access to PrOKEDI®, a critical treatment for schizophrenia in Canada.
Bausch Health Secures Key Agreement for Schizophrenia Treatment Across Canada
Bausch Health's recent agreement with the pan-Canadian Pharmaceutical Alliance marks a significant step in enhancing access to schizophrenia treatment across Canada.
Bausch Health Companies Inc. (BHC.TO) Slides 3.5% in Last Session Amid Ongoing Concerns
Bausch Health Companies Inc. saw a 3.5% decline in its stock price yesterday, raising concerns about its financial health and future prospects.
Why Bausch Health Companies Inc stock is sliding today
Bausch Health Companies Inc's stock has taken a hit, closing down 4.41% at CA$7.16. With a market cap of CA$2.8 billion and a troubling financial report highlighting substantial losses, investors are left questioning the company's future.
Why Bausch Health Companies Inc stock is sliding today
Bausch Health Companies Inc's stock slid 2.27% in the last trading session, closing at CA$7.32. This decline raises concerns about the company's financial stability and future growth prospects.
Bausch Health Companies Inc. (BHC.TO) Rises 5% in Last Session — What’s Driving the Momentum?
Bausch Health Companies Inc. (BHC.TO) gained 5% in the last session, driven by anticipation for its upcoming Q1 2026 results. Investors are optimistic about the company's growth potential.
Bausch Health Companies Inc. (BHC.TO) Gains Ground with a Strong Day of Trading
Bausch Health Companies Inc. saw a notable stock increase in the last session, signaling renewed investor interest amid ongoing financial challenges.
11 Best Value Stocks In Canada For June 2026
Most investors are fascinated with stories of people like Michal Burry, the man who predicted the housing market collapse of 2008 and made US $800 million by shorting the housing market. It’s a powerful example of how a unique perspective, an acute perception, and ingenious investment techniques can
![11 Best Value Stocks In Canada For [currentmonthyearfull]](https://lhajohzwizrsjmumhpjg.supabase.co/storage/v1/object/public/wealth-awesome/site-media/best-value-stocks-in-canada_4-8.jpg)